SEC 13F Intelligence

Managers / Q1 2024 · view latest →

Checkpoint Capital L.P.

CIK 0001977548 · 345 CALIFORNIA STREET, SUITE 600, SAN FRANCISCO, CA, 94104 · 914-355-0570

Reported Value
$150M
Q1 2024
Positions
17
Filings on Record
10
2019–present window
Filed
May 15, 2024
original filing

Summary

Checkpoint Capital L.P. reported $150M in U.S.-listed holdings across 17 positions for Q1 2024.

The portfolio is heavily concentrated: RYTM alone accounts for 23.9% of reported value.

Compared with Q4 2023, the fund opened 4 new positions and exited 5.

Portfolio Metrics

Turnover
+20.8%
vs prior filed quarter
Top-10 Concentration
+92.2%
share of reported value
Largest Position
+23.9%
Rhythm Pharmaceuticals
New / Exited
4 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’23: $165MQ4 ’23Q1 ’24: $150MQ2 ’24: $166MQ2 ’24Q3 ’24: $202MQ4 ’24: $196MQ4 ’24Q1 ’25: $182MQ2 ’25: $215MQ2 ’25Q3 ’25: $298MQ4 ’25: $320MQ4 ’25Q1 ’26: $279Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 69.2%ADR: 21.6%Other: 9.2%
  • Common Stock · 69.2% · $104M
  • ADR · 21.6% · $32M
  • Other · 9.2% · $14M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
HTDCORCEPT THERAPEUTICS INCNEW+273.8K273.8K+$7M$7M
VSTMVERASTEM INCNEW+168.7K168.7K+$2M$2M
APLTAPPLIED THERAPEUTICS INCNEW+220.0K220.0K+$1M$1M
ATRAGBXATARA BIOTHERAPEUTICS INCNEW+892.9K892.9K+$619,640$619,640
AVADEL PHARMACEUTICALS PLCADDED+376.4K701.4K+$7M$12M
SPDR BIOTECH ETF TRSOLD OUT−180.0K0−$16M$0
SWTXUSDSPRINGWORKS THERAPEUTICS INCSOLD OUT−340.0K0−$12M$0
IRONDISC MEDICINE INCSOLD OUT−10.0K0−$577,600$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2024

17 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RYTMRHYTHM PHARMACEUTICALS INChistory →COM23.91%$36M825.5K
2ARGXARGENX SEhistory →SPONSORED ADR21.58%$32M82.0K
3CYTKCYTOKINETICS INChistory →COM NEW8.90%$13M190.0K
4AVADEL PHARMACEUTICALS PLCSPONSORED ADR7.92%$12M701.4K
5AXSMAXSOME THERAPEUTICS INChistory →COM7.06%$11M132.4K
6MIRMMIRUM PHARMACEUTICALS INChistory →COM6.08%$9M362.2K
7PTGXPROTAGONIST THERAPEUTICS INChistory →COM5.42%$8M280.3K
8HTDCORCEPT THERAPEUTICS INChistory →COM4.61%$7M273.8K
9IRWDIRONWOOD PHARMACEUTICALS INChistory →COM CL A3.60%$5M618.5K
10PHATPHATHOM PHARMACEUTICALS INChistory →COM3.16%$5M445.2K
11ATYRATYR PHARMA INChistory →COM NEW1.89%$3M1.45M
12VSTMVERASTEM INChistory →COM NEW1.33%$2M168.7K
13GH RESEARCH PLCORDINARY SHARES1.32%$2M185.7K
14TRVITREVI THERAPEUTICS INChistory →COM1.17%$2M506.1K
15APLTAPPLIED THERAPEUTICS INCCOM1.00%$1M220.0K
16ALLKGUSDALLAKOS INCCOM0.65%$967,635768.0K
17ATRAGBXATARA BIOTHERAPEUTICS INCCOM0.41%$619,640892.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$279M8May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$320M7Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$298M10Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$215M8Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$182M14May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$196M16Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$202M16Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$166M16Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$150M17May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$165M19Feb 14, 202413F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.